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Caspase-1 Processing and
Signals through the ST2 Receptor
Activation of ST2, an orphanmember of the IL-1 recep-
tor family for 16 years, drives T helper type 2 (TH2) re-
sponses. The cytokine IL-33 is the specific ligand for
ST2. IL-33 recapitulates much of the existing data that
ST2 promotes TH2-type responses. The caspase-1
processing of precursor IL-33 provides a therapeutic
target to control allergic diseases.
The receptor termed ST2 is a member of the IL-1 recep-
tor family and was first reported as regulated by the
estrogen-inducible transcription factor Fos (Bergers
et al., 1994). This receptor is very similar to the IL-1 re-
ceptor type I and the IL-18 receptor a chain in that ST2
also has three extracellular Ig domains and an intracellu-
lar Toll domain (Figure 1). Described more than 16 years
ago, thesearch for itscognate ligand didnot revealacon-
vincingly specific candidate. Although some members of
the IL-1 family of ligands remain without known recep-
tors, none of these bind to or signal the cell via ST2. It
was always assumed that the ligand for ST2 would be
a member of the IL-1 family. But it is not unusual to learn
of the functions of an orphan receptor before the dis-
covery of its ligand. And so it was the case with ST2.
There was no dearth of studies on ST2 tissue-specific
localization, regulation of its expression, and effects in
transgenic mice overexpressing ST2, as well as deletion,
neutralization, and antibody crosslinking of ST2. We
learned that elevated levels of the soluble form of ST2
were present in the circulation of patients with a various
inflammatory diseases and that exogenous administra-
tion of pharmacologic doses of soluble ST2 neutralized
the putative ligand and reduced inflammation (Leung
et al., 2004). Furthermore, several studies suggested that
whatever the ligand for this orphan receptor, it was play-
ing a role in allergic type diseases, often called T helper
type 2 (TH2) diseases. In fact, it became clear that activa-
tion of ST2 was uniquely driving TH2 responses. Of the
TH2-driven diseases, asthma continues to be difficult to
treat. In this issue of Immunity, a member of the IL-1 fam-
ily, IL-33, is reported to be the specific ligand for ST2
(Schmitz et al., 2005). Structurally, IL-33 is closest to
IL-18, rather than IL-1b. With the discovery of IL-33, the
door appears to close on the 16-year-long search. But
the discovery of IL-33 also raises the curtain on a new
round of investigation on the immunological as well as in-
flammatory consequences of engagement of ST2. In this
case, the dominant property of IL-33 is the induction of
IL-4, IL-5, and IL-13 as well as properties anticipated
for a TH2-type cytokine. Diseases thought to be due to in-
creased immunoglobulin production may also be related
to IL-33.
Lacking an IL-33 knockout mouse, the investigators
injected mice with human IL-33 and observed rather
impressive pathological changes in the arterial walls,lungs, and intestinal tissues. Of particular relevance to
the concept that IL-33 drives a TH2 response, esosino-
philic infiltration was a prominent finding. In addition,
copious amounts of mucus were observed in the upper
airways of the lung. Again, this finding is consistent with
the classic TH2 disease, asthma. Large amounts of mu-
cus were also seen in the lumen of the intestine associ-
ated with hypertrophy of the mucus-producing goblet
cells. Although the interpretation of in vivo effects fol-
lowing the administration of an exogenous cytokine
should be conservative, the findings are clearly consis-
tent with IL-33 being a proinflammatory ligand of the
IL-1 receptor family. Even before the ability to test ST2
functions via IL-33-mediated activation, others had re-
ported that neutralization of the putative ST2 ligand by
soluble ST2 markedly reduced joint inflammation, syno-
vial hyperplasia, and joint erosion when given in the
therapeutic phase of collagen-induced arthritis in mice
(Leung et al., 2004). Moreover, it appears that organs
with high numbers of mast cells appear to undergo dra-
matic changes upon injection of IL-33 into mice. Consis-
tent with a role in allergic diseases, IL-33 induces the
cytokines IL-5 and IL-13 in vivo, known contributors of
allergic diseases. Mice deficient in ST2 do not develop
a TH2 response to Schistosoma egg antigen (Townsend
et al., 2000).
It remains unclear how IL-33 favors the TH2 response.
As shown in the Figure, following engagement of ST2,
IL-33 initiates signal transduction such as activation
of NF-kB typical of those of IL-1a, IL-1b, and IL-18
(Schmitz et al., 2005), but other studies have shown that
antibody crosslinking of ST2 does not result in activa-
tion of NF-kB but rather AP-1 (Brint et al., 2002). How-
ever, IL-33 gains considerable legitimacy as a member
of the IL-1 ligand family, since processing of the IL-33
precursor is accomplished by caspase-1 (Schmitz
et al., 2005), similar to IL-1b and IL-18. Caspase-1, for-
merly termed the IL-1b converting enzyme, cleaves
the inactive IL-1b and IL-18 precursors into active cyto-
kines. Indeed, caspase-1-deficient mice fail to develop
colitis, arthritis, acute renal failure, T cell-mediated hep-
atitis, and metastatic melanoma. In some of these dis-
ease models, capsase-1 deficiency is due to reduced
IL-1b processing and secretion, but in others, it is due
to reduced IL-18. Since the IL-33 precursor is also
cleaved by caspase-1 into an active cytokine, it remains
possible that lack of processing IL-33 into an active cy-
tokine may contribute to the protection afforded cas-
pase-1-deficient mice.
In humans, there are several severe systemic inflam-
matory diseases in which an increase in functional cas-
pase-1 activity appears to play an important role.
Increased release of processed IL-1b has been demon-
strated in monocytes of patients with these diseases
(Agostini et al., 2004; Hoffman et al., 2004), and treat-
ment of affected subjects with IL-1 receptor blockade,
neutralizing antibodies to IL-1b or the IL-1 Trap, returns
affected patients to normalcy (Dinarello, 2005). Some of
these diseases are inherited and the genetic defect re-
sults in a reduced capacity to control of activation of
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mechanism by which there is increased release of active
IL-1b, it is now clear that IL-33 processing and secretion
by caspase-1 must now be considered to contribute to
these diseases.
Why? From the first report of the existence of ST2
(Bergers et al., 1994), a high level of expression of this
receptor on mast cells has been a prominent finding.
The TH2 response favors antibody production, including
Figure 1. Production and Activity of IL-33 in the Generation of TH2
Responses
Cytokines such as IL-1b (but also TNFa) stimulate responsive cells to
synthesize IL-33. The initial translation product is the IL-33 precursor.
Assuming that IL-33 is similar to the other two members of the IL-1
ligand family, IL-1b and IL-18, the IL-33 precursor enters the special-
ized secretory lysosome together with components of the IL-1b
inflammasome (procaspase-1 and a member of the NALP family
[Tschopp et al., 2003]). Following activation of caspase-1 via a potas-
sium channel and calcium-dependent mechanism (Andrei et al.,
2004), the IL-33 precursor is cleaved, the membrane of the secretory
lysosome fuses with the cell membrane, and IL-33 is released as an
active cytokine. Mature IL-33 binds to ligand binding ST2 (which may
also be termed IL-33 receptorachain, IL-33Ra). Again, assuming that
IL-33R is similar to that of IL-1 and IL-18 receptors, a heterodimeric
signalling complex is formed with a second accessory chain, the lat-
ter of which can be hypothesized to also be a member of the IL-1 re-
ceptor family. Alternatively, the IL-33 receptor may share such an
accessory chain with those of IL-1 or IL-18. The cytoplasmic domain
of ST2 contains the Toll-IL-1 receptor sequence, essential for signal-
ling in members of the IL-1 receptor family. As described in the report
(Schmitz et al., 2005), IL-33 binding to ST2 results in activation of
MyD88, IRAK4, and TRAF6 as well as activation of NF-kB and MAPK
(mitogen-activated protein kinases). The question mark in the figure
indicates unknown signaling pathways that preferentially induce
gene expression for TH2 cytokines or alternatively suppress genes
of Th1 cytokines. Transcription and translation of IL-4, IL-5, and
IL-13 dominate in cells triggered by activation of ST2 and IL-33.
These cytokines stimulate other cells that execute the immunological
mandate for TH2 responses to antigen. Structurally, IL-33 is related to
IL-18, and IL-18 also evokes TH2 responses (Nakanishi et al., 2001).IgE and IgG. Mast cell activation is associated with IgE
and the clinical manifestations of skin rashes including
urticaria (itchy hives). In fact, the clinical syndromes of
the diseases due to increased caspase-1 activity often
include skin rashes and/or urticaria. Most notably are
the known inherited forms of these diseases such as
familial cold-induced autoinflammatory syndrome (Hoff-
man et al., 2004) and Muckle-Wells syndrome (Hawkins
et al., 2004). Patients with Schnitzler’s syndrome have
a gammopathy and chronic pruritic urticaria (de Koning
et al., 2005); hyper IgD syndrome is also likely associ-
ated with poor control of caspase-1. In systemic onset
juvenile idiopathic arthritis and adult onset Still’s dis-
ease, for which the mechanism for increased release
of IL-1b is not known, rashes characterize their clinical
descriptions. Although each of these diseases respond
to reducing the activity of IL-1b, IL-1b may drive IL-33
production (both being caspase-1 dependent), and it
is IL-33 that likely mediates the TH2 responses of these
diseases (Figure 1).
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